I thought we had gotten rid of the childish name calling. If you havent seen delayed results in a biotech before, you have never bought a biotech. Timing of results most likely up to the koreans, not JJ. And if the short delay allows a better deal with Novartis, would you still be whinning? Maybe wait for the results and see what happens.
Novartis bought a Dry Eye drug from Otsuka in 2005 called rebampide. They did a P3 and finished in '08 but no news after that. I assume it was a failure. Right now they only have a eye lubricant called GenTeal, which is over the counter and not much better than saline.
So, they are in the market and motivated...............a good combo.
Novartis is the obvious choice. They are going to fall behind shire and AGN in the dry eye market. Both Shire and AGN have compounds for dry eye that are pre approval for dry eye but very close. Shire is in front of the FDA now and AGN bought the rights to a compound for 50 mil last year that is in P3. So, Novartis has a ton of incentive here.
It make sense that small delay in trial results has Novartis written all over it. Just the mention of Novartis and rgrx in the same PR will give rgrx instant credibility.
Why would the koreans pay good money to expand a license if data is not good?. They have data or a very good idea of what that data is, so...........
Gtree not selling off; very quiet. And rgrx is hanging tough near the year highs as market gets crushed.
, Md., April 28, 2016 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx") today announced that it has expanded its license to ReGenTree, LLC for RGN-259 in North American from solely the U.S. to the U.S. and Canada. The license expansion was negotiated pursuant to a term sheet that was previously announced by RegeneRx in its most recent Form 10-K. RegeneRx previously received a payment from ReGenTree of $250,000 under the term sheet, which is the license fee for the expanded territory. The U.S. license between the two companies has been amended to include Canada, and the Canadian territory will be subject to the same royalty structure as currently exists
So, i will clarify DonkSpeak for the readers. Donk says, yes he has stock. Of course at a low cost basis lol
But, since he refuses to acknowledge what every biotech investor on the planet knows, that the Dry eye results are a binary event, he sees no conflict. The NK is meaningless in the near term and doesnt negate the fact that dry eye is binary....regardless of what your google search came up with for the term binary. Its not surprising that you dont know the term as it relates to biotech, since all your comments on same show your lack of experience in the sector.
Carry on donk
Some of us who actually own the stock might be a little more than "kinda" interested. If it is possible for you ever to answer a direct question or 2.........
Clarify how you say you are long stock, but in the same post say you are not a gambler and dont invest before binary event. So, are you long or not? If long, how do you justify binary statement?
Donk, by his own admission, knows nothing about the science of TB4,Dry Eye, the trial protocals, or the FDA. He can not answer the simple question as to what a "flop" is. He says "criteria." Again, by his own admission, he is not long stock as he doesnt "gamble" and doesnt invest before a binary event. This is clearly an upcoming binary event, but he says he is long. Is Donk a liar? Or a very astute trader? Or just a failed, patent attorney wanabe? Or hoping for a "flop" so he can buy his 100 shares back?
There is no herd mentality here, as there are very few retail in this stock. The board itself has had only a few regulars for many years....PreDonk. If there is any group think here it is the rapidily forming consensus that Donks opinion is as worthless as a pretend patent he might have worked on.
If you are the patent guy, why not focus on one of the patent trolls, like VHC. Lots of action there for a big trader like you donk.
He says he doesnt play binary events. In the biotech world, these rgrx trials results are a binary event. So, he is not a long. Yet, he talks using "we". The guy cant even keep track of his lies.
He talks about being a patent expert, but no real knowledge of trial design or science in any way. He talks about "criteria." when asked about what is a flop. That is a nice word but has no application here. He doesnt know anything about the possible pros or cons of upcoming trial results.
Of course he is responsible, as CEO, for failures. And there were many. But, taking pay cut was the action that showed accountability. That is something concrete, not just a political talking point.
Nobody knows the dynamics of trial setups and indications over the years; certainly not a newbie like you donk. If you had really done some DD here, you would know that Sigma tau influence was very large. They, and specifically the now deceased C bros(angel investor here) wanted have big cures for large, difficult unmet medical needs. That is why all previous endpoints(wounds) were set on the most horrible, difficult indications.....huge, open wounds instead of easier, less severe healing endpoints. He wanted a homerun when a single was easily within reach.
This is all part of the DD that give a potential investor the answer as to why did all other trials fail. Do they have anything to do with this trial? Could giving trial work to ORa and having a much more accomodative FDA in the dry ey area make a difference?
Not giving JJ a pass but he had to answer to the money source, and that was Sigma tau. More importantly, no analyst on the street had dug into any of this....rgrx..underowned, and underfollowed. That is a recipe for huge buying if trial endpoinds met.
And your question about what to do if trial flops justs smacks of unsophistication and negative(short) bias? What does flop mean? How about nuanced results? How about 1 endpoint met and not the other but secondaries strong? Is that a flop? What if OSDI is hit? No other drug as ever done that.Could FDA change endpoint to OSDI as they changed endpoint for shires drug? We have a good chance since visual acuity increases with TB4. Is that a flop? What about eye pressure?
Bios are never as simple as your questions imply.
Hey donk, you havent been here very long if thats the best you can come up with; me dissing JJ. My position, and i have said it a few times, has changed. Now, if you would put that 1/2 a brain of yours at work, you might ask why? It changed when he went from a CEO's compensation, to a hourly, salaried position. He did this to allow company to survive. In the history of biotech companies, and the 100's i have followed over a few decades, i have never, ever seen a CEO take this kind of paycut(to say nothing of the loss of prestige). Maybe you can come up with another example. The bottom line is here that that paycut was done to allow rgrx to survive. All other CEO's would have just allowed company and shareholders to go bust. many, many examples of that So, regardless of weather results are good or bad, we would not even be, maybe hours away from key results without that sacrifice. So, when a man shows me, by his actions, that he has interests other than himself in mind, i believe he deserves a second look.
Hell, i might even change my mind and reconsider my opinion of you being such a B hole someday..............or not
carry on donk
OMG. Zombie apocalypse starting as TB4 eye drops found to infect the brain of subjects. Now, thats what i call an Adverse Event. lol
RGRX's stock will go down if trial "flops". Thats basically the message of his post, along with the usual boring, unimaginative, mundane insults on all of us.
Donk, you are a newbie here, a relative annoying new comer to rgrx. You didnt live through the failed wound trials or the stopage of the RGN 352 trials due to manufacturer lossing compliance with the FDA. Long timers here are not polyanna's, we have seen many failures and disappointments and we do not discount the fact that another one could be at hand. Its the nature of bio investing.
But, no trial in the history of rgrx has had a better chance of success. All DD points to that fact. I dont care to go over it all with you since you are a 1/2 glass full kind of guy who clearly thinks to much of himself. I will say that Seok taking over as the sole CEO is not alarming. Very few companies have 2 ceo's and the emphasize here is clearly biotech, not old tech. So, made good sense. And if bond converter sold stock after a 5x gains it is not surprising. That company was not an invester, they were a mezzanine financer. By definition, they take money out as soon as possible; just like Lincoln. It amazing stock held up so well. So, plenty of serious Investors took there place.
So carry on Donk. New readers should be aware that you should fact check donk.
Luck to longs
You could be right, maybe 1.5 is low, but i think realistic in the near term.
As a long time bio investor, you are way off on your comments on the P value. Anything, and i mean any number below .05 will be statisically significant and a huge win. No pharma/biotech goes around claiming their drug may have a competitive advantage because it hit a lower number. The number is just to satisfy the FDA. For them, its either success or failure.
Stock closed on the high of the week; up a penny. That is a great close considering stock traded down to a low at the 200DMA of .45. Now, the real fun begins.
I stick to my projection of 1 1/2 on good data.
Luck to all Longs. Have a good Weekend.
Gee donk, i thought we were getting along after agreement on your term sheet theory....which proved to be all wrong.
You may not like my posts but they do not contain the factual errors yours seem to do recently. Not knowing that the 10k had trial results clearly stated at the end of April is a small mistake. But, stating as fact that is was not in 10k, leaves you about as credible as teach.
Cheer up donk, soon positive results here wont leave any more need for your worthless conspiracy theories or your other obtuse nonsense.................carry on donk
Donk, if you have a strong feeling about benefits, lets hear it. Why always so cryptic?
Money comes from Koreans either way; JV has assets of dry eye, and terms set out earlier. The canadian rights were never going to go outside the JV.
The analyst at Rodman(Ram Selvaraju) who is today, right in front of data, reiterating buy is well rated in the sector. Tipranks is a paid service that covers 50k sell side analysts and they give him 4 out of 5 stars.
So, he is really putting that rating on the line going into trial results. He also had scln as a buy. History to repeat????
250K coming from Regentree vs G-Tree.?
When did the JV get funded with cash? Did I miss that? How much do they have? I didnt know they had any.
RGRX saying cash came form Regentree must have a purpose for the Koreans, maybe some accounting thing, but cash obviously came from G-tree.
I am still amazed at the obvious outright positive implications of additional money coming to RGRX from the Koreans that will only pay off if trial is successful. Now, if results were a couple months out, i wouldnt put much weight on money, but these results are coming any day and Koreans have more than a good "guess" at what results are. Why waste even another dime to TB4 rights for dry eye if results dont look very positive?
The fact that rgrx isnt a buck now on that PR, is a function of the total lack of following this company and this trial has on Wall st. That will change big time next week and will certainly make Shire take notice.
mia, maybe if that wife of yours got that boot of hers off neck, you might be able to think more clearly. As far as posts that have rewarded readers, i direct you to my strong buys at under 10 cents and at the 45 cent pre breakout level. You can find them yourself; they are there.
You are and always have been a equally worthless poster and human being.
And one last chance for the stupid amoung us, who havent averaged down yet(thats you mia), if gtree strong tonight, buy with both hands tomorrow. Mia, ask your wife first.
And last comment to that great bio investor mia. No sale in front of data exudes confidence. And yet, many CEO's of bio's do it. But not here, and that is the point mia.